Tests HPV vaccine given alongside HPV screening in Swedish women
Tests Gardasil 9 vaccine with HPV screening in women aged 22 to 27.
Plain-language title generated from the registry record
Registry title: Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden
Key facts
- Where
- Falun, Gavle, Halmstad, Jonkoping, Kalmar, Karlskrona, Karlstad, Linkoping, Lulea, Malmö, Nykoping, Orebro, Ostersund, Stockholm, Sundsvall, Umea, Uppsala, Vänersborg, Vasteras, Vaxjo, and Visby, SwedenSee the 21 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 22 and 27 years old?
Source: NCT04910802, who can take part
Where in Sweden
- Region DalarnaFalun, SwedenTaking people
- Region GaevleborgGavle, SwedenTaking people
- Region HallandHalmstad, SwedenTaking people
- Region Joenkoepings LaenJonkoping, SwedenTaking people
- Region Kalmar LaenKalmar, SwedenTaking people
- Region BlekingeKarlskrona, SwedenTaking people
- Region VaermlandKarlstad, SwedenTaking people
- Region OestergoetlandLinkoping, SwedenTaking people
- Region NorrbottenLulea, SwedenTaking people
- Region SkåneMalmö, SwedenTaking people
- Region SoermlandNykoping, SwedenTaking people
- Region Oerebro LaenOrebro, SwedenTaking people
- Region Jaemtland HaerjedalenOstersund, SwedenTaking people
- Region StockholmStockholm, SwedenTaking people
- Region VaesternorrlandSundsvall, SwedenTaking people
- Region VasterbottenUmea, SwedenTaking people
- Region UppsalaUppsala, SwedenTaking people
- Vaestra GoetalandsregionenVänersborg, SwedenTaking people
- Region VaestmanlandVasteras, SwedenTaking people
- Region KronobergVaxjo, SwedenTaking people
- Region GotlandVisby, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Miriam Elfström
- Trial code
- NCT04910802EU 2024-518857-41-00
- Record updated
- 16 September 2021
- Original description
The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.Read full original descriptionShow less
Concomitant HPV Vaccination and HPV Screening for Rapid Elimination of HPV Infection and Cervical Cancer in Sweden
The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.
Inclusion: Eligible women will include resident women within the age range of 22-26, who have not opted out of the screening program and who consent to participate in the study; Women who respond to the invitation and attend screening will be screened with HPV testing by the current routine practise. Women who consent to participate will also be offered HPV vaccination. The HPV vaccine (Gardasil 9) will be offered regardless of whether the woman reports having had prior vaccination with a first-generation vaccine (Gardasil 4) and regardless of screening test result.
Exclusion: Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose; Known history of immune-related disorders; Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever; Known history of severe allergic reaction or hypersensitivity to any of the components of the HPV vaccine.For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate; Current pregnancy (reported); Women with a total hysterectomy.